CurrentBlue Cross Blue Shield - IowaPolicy 07.01.73

Ablative Procedures of the Peripheral Nerves to Treat Pain

Clinical coverage and evidence review of peripheral nerve ablative procedures (radiofrequency ablation, cryoneurolysis/cryoablation, and chemical neurolysis) for treatment of various non-spinal pain syndromes; intended for Blue Cross Blue Shield - Iowa providers and medical reviewers.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyAblative Procedures of the Peripheral Nerves to Treat Pain

Policy CodePolicy 07.01.73

Change TypeNo material changes noted

Effective DateJan 1, 2017

Next Review DateN/A

Key ActionObtain prior authorization and document failed conservative therapies and baseline/posttreatment pain scores when requesting coverage.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

multipleconditions reviewed

insufficientevidence conclusion

RCTsRCTs cited

multipleinvestigational indications

Prior approval requiredauthorization requirement

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Evidence Summary

inv-01: Evidence summaries by indication

Summary of evidence and conclusions for indications reviewed in this policy excerpt:

Osteoarthritis of Knee — RFA: Multiple randomized trials, systematic reviews, and nonrandomized comparative studies report short‑term (3–6 month) improvements in pain and function following genicular nerve RFA; two multicenter U.S. trials of cooled RFA reported ~70% responder rates at 6 months. However, heterogeneity in methods, comparators, and limited long‑term blinded data leave net health benefit uncertain.

See RCTs, network meta-analyses, and extension studies through 24 months; evidence judged insufficient for definitive long-term benefit.

Osteoarthritis of Knee — Cryoneurolysis: Two RCTs (total n≈304), cohort studies, and registry data show early post‑procedure pain and opioid‑use reductions (eg, pre‑TKA settings), but benefits are inconsistent beyond early timepoints and technical parameters (targets, freeze duration) remain unresolved.

Short-term benefit demonstrated in some RCTs; durability and optimal technique uncertain.

Knee — Chemical neurolysis: Evidence consists mainly of case series and a small prospective cohort; limited comparative RCT data exist and long‑term outcomes are lacking—insufficient to establish net health benefit.

Observational cohort (n=43) reported pain reduction up to 6 months but was noncomparative.

Hip OA — RFA and chemical neurolysis: Evidence includes small nonrandomized studies and limited RCT data (including an ethanol neurolysis RCT showing NRS reductions and lower opioid use through 6 months); overall evidence is promising but insufficient and requires larger multicenter RCTs with longer follow‑up.

Single-center RCTs report significant short-term improvements but generalizability and durability remain uncertain.

Chronic Shoulder Pain — RFA: Systematic reviews and small cohort studies suggest possible benefit for suprascapular or related nerve RFA, but heterogeneity of protocols, small samples, and inconsistent reporting limit conclusions; evidence insufficient to determine net health outcome.

Multiple small RCTs and case series included in reviews but methodological limitations predominate.

Intercostal Neuralgia — RFA: Evidence limited to case series (including cooled and standard RFA) with short follow‑up; data insufficient to establish efficacy or durability.

RCTs lacking; further research needed.

Chronic Inguinal Neuralgia — RFA/PRF: Two small RCTs (Makharita 2015, Kastler 2012) and observational reports show mixed results with methodological limitations; evidence insufficient to confirm net health benefit.

Some trials report longer duration of relief with PRF but samples are small.

Plantar Fasciitis — RFA/cryoablation: Two small double‑blind RCTs and a meta‑analysis report short‑term pain reductions, but pooled evidence is low quality with high heterogeneity; conclusions about durable clinical benefit cannot be made.

RCT follow‑up limited to weeks–months and sample sizes small.

Peripheral Neuromas — RFA/cryoablation: Evidence limited to case series with variable responses; randomized comparative data lacking—insufficient to determine net health benefit.

Some patients achieve relief but results inconsistent.

Chronic Orchialgia — PRF: One double‑blind RCT (Hetta et al. 2018) showed significant short‑term (up to 3 months) VAS reduction versus sham for pulsed RF of ilioinguinal/genitofemoral branches; limited follow‑up and outcome scope make net benefit uncertain.VAS >5 entry criterion used in trial

Trial required prior failed conservative therapy and >50% response to diagnostic spermatic cord block.

Postherpetic Neuralgia — PRF: Systematic reviews of small RCTs (4 RCTs) suggest short‑term pain benefit (effects beginning Day 2–3 and persisting 2–6 months) with low‑quality evidence and heterogeneity; long‑term efficacy remains unestablished.

Additional adequately powered RCTs with longer follow‑up needed.

Cryoablation for Nuss procedure (intercostal nerve cryoablation): Meta‑analyses, one RCT and multiple observational studies show reduced hospital length of stay (MD ≈ -2.9 days) and lower inpatient opioid use versus thoracic epidural in many studies, but heterogeneity and variable complication rates (eg, 11% vs 3.1%) limit certainty; evidence supportive but requires larger RCTs for conclusive assessment.

Subgroup analyses indicate heterogeneity related to concomitant analgesic methods.

inv-02: Investigational / Not medically necessary indications

The following uses of peripheral nerve ablation are considered investigational (not medically necessary) because evidence is insufficient to determine net health benefit:

Investigational indications list: Chronic knee pain/osteoarthritis of the knee (including pre‑, post‑, or in lieu of joint replacement), chronic hip pain/osteoarthritis of the hip (including pre‑, post‑, or in lieu of joint replacement), chronic orchialgia, chronic shoulder pain, inguinal neuralgia, intercostal neuralgia, peripheral neuromas, plantar fasciitis, postherpetic neuralgia, and pre‑operative/intraoperative/post‑operative pain management related to pectus surgery including Nuss procedure.

Policy lists these indications as investigational.

inv-03: Evidence-based coverage criteria

Covered when ALL of the following evidence‑based considerations are met:

Primary criteria: 1) Patient has symptomatic knee osteoarthritis refractory to conservative management (eg, analgesics, physical therapy, weight loss, supportive devices, and, where appropriate, intra‑articular corticosteroid or hyaluronic acid injections); 2) Targeted treatment addresses genicular or intra‑articular sensory nerves (eg, superomedial, inferomedial, superolateral genicular nerves); 3) Baseline and planned follow‑up quantifiable outcome measures are documented (eg, VAS/NRS, WOMAC, Oxford Knee Score); 4) RFA modality and technique are specified and consistent with available randomized evidence (cooled RFA, conventional RFA, pulsed RF) and with image‑guided targeting; 5) Reasonable expectation of benefit based on randomized evidence demonstrating short‑ to medium‑term reductions in pain and improved function.

Derived from RCTs, systematic reviews and extension studies; diagnostic block response used in many trials and responder rate ~70% at 6 months for cooled RFA in some multicenter studies.

inv-04: Trial-based eligibility and selection

Evidence and selection criteria reflected in the cited randomized trials and extensions:

Trial-based selection criteria

Conservative therapies: Documentation of prior conservative care (physical therapy, analgesics stable for 2 months, and prior intra‑articular steroid or viscosupplementation) was required in trials.stable for 2 months for oral analgesics
Per trial enrollment criteria.
Diagnostic block response: At least 50% reduction in pain with anesthetic injection to targeted genicular branches was used as an inclusion criterion in several trials.>=50% pain reduction
Used in cooled RFA pilot and other trial protocols.

inv-05: Evidence-based coverage considerations

Evidence and clinical‑context considerations extracted from the review:

Evidence sufficiency: Randomized trials and systematic reviews report benefit for pain and function at 3–6 months but with moderate‑to‑high heterogeneity and methodological limitations (eg, lack of blinding, variable comparators); longer, adequately powered blinded trials are needed.

Longer follow‑up (≥12 months) preferred for durability assessment.

Comparative effectiveness signals: Network meta‑analyses suggest cooled RFA may have greater efficacy through 6 months compared with traditional or pulsed RFA; nonrandomized studies show mixed results for durability and magnitude of effect.

Heterogeneous results across studies (Kapural, Wu et al. analyses).

Safety and durability concerns: Case reports and pooled RCT data describe adverse events (eg, septic arthritis, burns, hematoma) and variable durability beyond 6–12 months; repeat treatment effectiveness and optimal retreatment timing are not established.

Attrition in extension studies and limited long‑term blinded data.

inv-06: Evidence synthesis

Findings from systematic reviews and trials summarizing efficacy and limitations:

Clinical evidence summary: Systematic reviews and randomized trials report mixed results: some RCTs reported improvements in pain, function, or opioid use at early time points (eg, 72 hours to 12 weeks) and some secondary measures to 6–12 months; however, methodological limitations, inconsistent intent‑to‑treat results, and heterogeneity limit definitive conclusions.

Extension/longer‑term data show attrition and variable sustained responder rates.

Benefits observed: Improvements reported in pain (VAS/NRS), WOMAC/KOOS JR, and reduced opioid consumption in some per‑protocol analyses and at certain timepoints.

Observed in cryoneurolysis and some RFA trials.

Limitations and uncertainty: Many studies are small, single‑center, non‑blinded or have missing data; treatment parameters and patient selection vary, reducing generalizability and certainty.

Repeat treatment benefit and optimal technique unresolved.

inv-07: Contextual coverage criteria

Consider ablative peripheral nerve procedures when ALL of the following contextual items are present:

Patient selection: Chronic symptomatic knee or hip osteoarthritis with documented pain and functional impairment despite conservative management (eg, analgesics, physical therapy, weight loss, intra‑articular injections).failed conservative therapy documented

Conservative therapies expected per guideline and trial comparators.

Baseline and outcome measurement: Quantifiable baseline pain/function measures (VAS/NRS, WOMAC, KOOS, SF‑12) and a plan for postprocedure follow‑up assessments (early within 1 month and at least 6–12 months) to evaluate procedural effect and durability.6-12 months follow-up preferred

RFA effects often transient; longer follow‑up recommended.

Intervention types considered: RFA (standard, cooled, pulsed), cryoneurolysis, or chemical neurolysis targeted to relevant sensory nerves, with modality selection informed by available randomized evidence and operator expertise.

inv-08: Coverage considerations / procedural candidacy

Evidence‑based considerations for procedural candidacy and documentation expectations:

General candidacy: Patient has chronic hip or shoulder pain refractory to documented conservative management (physical therapy, medications, weight loss, assistive devices, and/or steroid injections).failed conservative therapy documented

Consistent with study comparators and guideline expectations.

Diagnostic block for certain procedures: When used as a selection tool (eg, cooled RFA), a diagnostic anesthetic block demonstrating >50% immediate pain relief should be documented to support candidacy.>50% immediate relief

Used in cooled RFA pilot and several trials for target confirmation.

Outcome measurement and follow‑up: Baseline and postprocedure validated outcome measures (VAS/NRS, WOMAC, HOOS, SF‑12/36) must be recorded with early (days–weeks) and longer‑term follow‑up (at least 6 months, preferably 12 months) to assess durability.

inv-09: Implied medical necessity criteria for peripheral nerve ablation

Covered when ALL of the following are met (implied from trial selection and clinical context):

General coverage criteria: 1) Diagnosis of a chronic focal peripheral neuropathic or joint‑related pain syndrome relevant to the targeted nerve; 2) Pain refractory to conservative management (systemic medications, topical agents, physical therapy, and, where applicable, diagnostic or therapeutic nerve blocks); 3) Quantifiable baseline pain score (VAS or NRS) and documentation of functional limitation; 4) Procedure‑specific informed consent and documentation of intended technique (RFA modality, cryoneurolysis, or chemical agent and concentration); 5) Postprocedure pain scores and follow‑up plan within days and at least 6–12 months to assess durability.

Implied from study inclusion criteria and reporting standards rather than explicit payer rule in this excerpt.

inv-10: Evidence-based considerations

Evidence summaries and considerations for select peripheral indications:

Inguinal neuralgia - evidence summary: Two small RCTs evaluated PRF/RFA for chronic inguinal neuralgia and reported longer duration of pain relief with active treatment in limited samples; studies were small and require confirmation in larger trials.

Makharita (2015) and Kastler (2012) provide trial data but sample sizes limit generalizability.

Plantar fasciitis - evidence summary: Two double‑blind sham‑controlled RCTs and a meta‑analysis (pooled 2 RCTs, n≈117) evaluated RFA for plantar fasciitis; some trials show short‑term statistically significant pain/function improvements but pooled evidence is low quality with high heterogeneity.

Larger, longer RCTs needed to establish durable benefit.

Chemical neurolysis - evidence gap: No peer‑reviewed studies identified for chemical neurolysis for several peripheral indications (eg, inguinal neuralgia); evidence insufficient—randomized trials needed.

Policy flags lack of data across multiple indications.

inv-11: Evidence-based coverage statements

Summary of coverage‑relevant evidence and implications for selected indications:

RFA for plantar fasciitis: Two small RCTs (total N≈53) and case series report mixed results; meta‑analysis did not demonstrate significant pooled benefit and evidence quality rated low—larger, longer RCTs needed to establish efficacy and safety.

Current evidence insufficient for definitive coverage conclusions.

Chemical neurolysis for plantar fasciitis: No published studies identified; evidence is insufficient to determine net health outcomes and RCTs are required.

No peer‑reviewed data available in the review.

Ablative procedures for peripheral neuromas: Evidence limited to case series showing variable responses; randomized comparative data lacking and longer follow‑up needed before concluding net benefit.

Insufficient evidence for routine coverage.

inv-12: Evidence summaries by indication

Evidence summaries and applicability for select neuropathic pain indications:

Chronic post‑surgical orchialgia: Pulsed radiofrequency (PRF) applied to ilioinguinal and genitofemoral branches showed significant short‑term VAS reduction versus sham in one RCT; inclusion required baseline VAS >5 and prior failed conservative therapy plus >50% response to spermatic cord block. Follow‑up limited to 3 months.VAS >5; >50% transient response to diagnostic block

Promising short‑term evidence but durability and broader applicability uncertain.

Postherpetic neuralgia (PHN): Systematic reviews and small RCTs of pulsed RF show short‑term pain benefit (effects from Day 2–3 persisting 2–6 months) though evidence quality is low and heterogeneous; additional adequately powered and longer trials needed.improvement often measured up to 6 months

No serious adverse events consistently reported in small trials.

Chemical neurolysis (orchialgia and PHN):

inv-13: Evidence summaries

Findings from RCTs, systematic reviews, and observational studies relevant to procedural choices and outcomes:

Cryoablation for Nuss procedure: Meta‑analysis and studies report shorter hospital length of stay (mean difference ≈ -2.91 days) and substantially reduced inpatient opioid consumption with intercostal nerve cryoablation versus thoracic epidural in many reports; however, study heterogeneity and variable complication rates limit certainty and warrant cautious interpretation.

Evidence includes one RCT and multiple observational studies; heterogeneity high.

RFA for post‑herpetic neuralgia: Pulsed radiofrequency showed favorable outcomes in small RCTs and systematic reviews with short‑term benefit (2–6 months), but RCTs are limited by small size and short follow‑up; more data needed for firm coverage decisions.

Additional adequately powered RCTs with longer follow‑up needed.

inv-14: Coverage considerations and clinical criteria

Coverage considerations and clinical criteria derived from evidence and guideline statements:

Cryoablation for Nuss procedure: Consider intraoperative intercostal nerve cryoablation as an adjunct for postoperative analgesia in select patients undergoing Nuss procedure when supported by documentation of indication and expected benefit; weigh reduced LOS and opioid use against heterogeneity and potential for higher complication proportions in some series.

Professional guidance and meta‑analytic signals support selective use but emphasize need for higher‑quality RCTs.

Cryoablation/cryoneurolysis for peripheral joint or soft‑tissue pain: Randomized and prospective trials exist for knee OA and other indications but quality and durability vary; professional societies give conditional or limited recommendations, suggesting selective offering after failed conservative therapy.

ACR/AAOS conditional recommendations referenced.

Radiofrequency ablation for knee OA and genicular nerves: Guideline statements provide conditional support for genicular RFA for OA‑related knee pain; consider after documented conservative care and when diagnostic blocks support target nerve involvement and technique aligns with available RCT evidence.

This medical policy may not apply to Federal Employee Program (FEP) members; benefit determinations for FEP participants are made separately by the Federal Employee Program and should be verified with the member's plan administrator.

The policy explicitly identifies the listed peripheral nerve ablation indications as investigational. Uses enumerated in the policy (for example, chronic knee or hip osteoarthritis, chronic orchialgia, chronic shoulder pain, inguinal and intercostal neuralgias, peripheral neuromas, plantar fasciitis, postherpetic neuralgia, and perioperative management for pectus/Nuss procedures) are considered investigational because available evidence is insufficient to determine net health benefit.

Procedures such as radiofrequency ablation are described in this document as symptomatic treatments rather than disease‑modifying or curative for osteoarthritis; interventions intended to alter the underlying disease course of OA are outside the scope of RFA's therapeutic intent as discussed in the evidence review.

Many randomized trials applied trial‑level selection criteria that required demonstration of a positive response to diagnostic anesthetic nerve block before enrollment; studies that did not select by diagnostic block or excluded patients without such a response limit applicability of trial results to patients without documented block response.

For cryoneurolysis using the iovera system, systematic reviews and evolving evidence reviews did not identify comparative studies against established standard‑of‑care alternatives for some knee OA contexts; available studies are heterogeneous and of variable quality, so the comparative effectiveness versus standard care remains uncertain.

The evidence base did not include studies evaluating the clinical benefit of repeat iovera (cryoanalgesia) treatments for knee osteoarthritis; durability and optimal retreatment timing for repeat cryoneurolysis are not established.

The review excluded or downgraded studies lacking methodologically credible designs (for example, single‑arm reports without standardized pre/post outcome measures or short follow‑up); procedures reported only in uncontrolled series or case reports therefore do not provide adequate evidence to establish effectiveness.

Evidence for ablative procedures in hip osteoarthritis is limited principally to small nonrandomized studies and short follow‑up; when evidence is restricted to these designs, the procedure should be considered investigational until corroborated by larger randomized trials with longer observation.

No peer‑reviewed studies were identified for chemical neurolysis (phenol, alcohol, glycerol) applied to chronic shoulder pain, and similarly none were identified for intercostal neuralgia in the literature review; therefore chemical neurolysis is unsupported by published studies for these indications.

A systematic review of the literature did not find published peer‑reviewed studies of chemical neurolysis for chronic inguinal neuralgia; absence of primary studies means the technique is unsupported by evidence for this indication.

The review identified no published studies of chemical neurolysis (alcohol, phenol, glycerol) for plantar fasciitis or for treatment of peripheral neuromas; these indications are therefore not supported by peer‑reviewed evidence.

No peer‑reviewed studies were found evaluating chemical neurolysis for chronic orchialgia or for postherpetic neuralgia; in the absence of published evidence, chemical neurolysis is unsupported for these indications.

Because many studies across indications were of low methodological quality, heterogeneous in design and outcomes, and limited in randomized controlled evidence, the authors recommend that well‑designed randomized trials with adequate sample sizes and longer follow‑up are needed to resolve uncertainties and establish effectiveness.

Caution is advised for pediatric application of intraoperative cryoablation (eg, in adolescents undergoing Nuss procedure) because existing evidence is limited; the document highlights the need for larger confirmatory studies before broadly extrapolating safety conclusions to children.

The references section does not include explicit statements excluding non‑medical‑necessity content; it lists the cited literature supporting the evidence review and does not add separate exclusionary language beyond the policy text.

Across the peripheral indications reviewed (including knee chemical neurolysis, hip RFA/chemical neurolysis, shoulder RFA, intercostal and inguinal neuralgias, plantar fasciitis, peripheral neuromas, orchialgia, and postherpetic neuralgia), the body of evidence is generally insufficient to conclude consistent, durable improvements in pain and function for most procedures; where randomized data exist they are often small, short‑term, or heterogeneous in methods, limiting definitive coverage conclusions.

The policy restates the enumerated investigational uses, which include: chronic knee and hip osteoarthritis (pre‑, post‑, or instead of joint replacement), chronic orchialgia, chronic shoulder pain, inguinal and intercostal neuralgias, peripheral neuromas, plantar fasciitis, postherpetic neuralgia, and perioperative/intraoperative/postoperative pain management related to pectus (Nuss) procedures.

When requests are considered for ablative procedures, documentation should include a history of prior conservative management (for example, physical therapy, analgesics, and, where applicable, intra‑articular injections), as well as quantifiable baseline pain and function measures (eg, VAS/NRS, WOMAC, KOOS) and a plan for follow‑up outcome assessment to demonstrate treatment effect.

Durability evidence is limited for several procedures described in the review; when longer‑term outcomes or randomized controlled evidence are absent, the document states these procedures may be considered investigational because sustained clinical benefit has not been established.

For chemical neurolysis in knee osteoarthritis, current data are limited to small cohorts and noncomparative series (for example, the 7% glycerinated phenol cohort), and the policy calls for larger randomized controlled trials with longer follow‑up to establish efficacy and safety before routine adoption.

Radiofrequency ablation and chemical neurolysis modalities that lack adequately powered randomized controlled trial evidence or only report short‑term outcomes should be considered not established for durable clinical benefit until higher‑quality randomized evidence with longer follow‑up is available.

For intercostal neuralgia, the available evidence consists primarily of small case series and reports; randomized trials are lacking and the evidence is insufficient to conclude efficacy for RFA in this condition.

The literature search did not identify peer‑reviewed studies supporting chemical neurolysis for inguinal neuralgia; therefore chemical neurolysis is unsupported for this indication.

Procedures reported only in uncontrolled single‑arm series, case reports, or small case series, or those with nonstandardized outcomes, inconsistent technical descriptions, or short follow‑up should be considered investigational until adequate randomized controlled evidence and standardized outcome reporting are available.

Overall, the evidence across many peripheral indications is insufficient to form definitive conclusions about long‑term clinical benefit and safety; where randomized data exist they are often short‑term or heterogeneous, and many indications lack controlled trials entirely.

The references section contains the citation list supporting the evidence synthesis; it does not include separate non‑medical‑necessity statements beyond the policy's investigational and not‑medically‑necessary designations.

Coding and Regulatory References

No explicit CPT/ICD codes listed in this portionmixed

No codes listed

Codes referencedmixed

See Codes table

Procedure and billing codes referenced in the policy's Codes table

FDA 510(k) examplesmixed

K163461

510(k) for COOLIEF cooled radiofrequency probe

Devices and systems mentionedmixed

iOVERA system (Myoscience, Inc.)

Device/system referenced for cryoneurolysis/cryoablation

Genicular Cooled RFA — 6 month responder rate

Responder rate at 6 months (genicular cooled RFA trials)Approximately 70% responder rate reported at 6 months in two multicenter U.S. cooled‑RFA trials

Diagnostic Block Response Threshold

Diagnostic block response threshold>= 50% immediate pain relief with anesthetic diagnostic block used as an inclusion/selection criterion in multiple trials

Orchialgia RCT — Entry Pain Severity (VAS)

Orchialgia trial entry pain severityBaseline pain required: VAS > 5 in the randomized orchialgia RCT

Prior Authorization, Documentation, and Billing Actions

Prior Authorization

Prior Authorization May Be Required

Prior authorization may be required — verify member benefits and obtain prior approval when required. Refer to the payer authorization table and Codes table for applicable prior approval requirements and billing/coding references.

Obtain prior approval when the member's contract requires it.
Reference the payer Authorization Table and procedure Codes table for specific code-level prior approval guidance.

Documentation Required

Prior Conservative Therapy Documentation

Document prior conservative therapy attempts and selection criteria before requesting authorization. Conservative therapies are the usual comparator and are expected prior to ablative procedures.

Conservative measures: analgesics, physical therapy, weight loss, activity modification, assistive devices, NSAIDs, topical agents, intra‑articular injections (steroid, viscosupplementation) as appropriate.

Background and Definitions

Background: Ablative peripheral nerve techniques summarized in this review include radiofrequency ablation (standard, cooled, pulsed), cryoneurolysis/cryoablation (eg, iovera), and chemical neurolysis (agents such as phenol, alcohol, glycerol). These interventions target peripheral sensory nerves to reduce pain from a variety of non‑spinal pain syndromes; evidence quality, sample sizes, and follow‑up duration vary substantially across indications.

Radiofrequency Ablation — Definitions (standard, pulsed, cooled)

Standard RFA definitionThermal lesioning using an electrode to coagulate tissue via high‑frequency current to ablate peripheral sensory nerves (temperatures typically 70–90°C)

Pulsed RFA (PRF)Delivers short pulses (eg, 20 ms every 30 seconds) at lower tissue temperatures (~42°C); thought to be neuromodulatory with less nerve destruction

Cooled RFA (C‑RFA)Uses water‑cooled probes to maintain lower probe temperatures while delivering greater energy to create larger lesion volumes compared with standard RFA

Cryoneurolysis / Cryoablation — Definition

Conservative Therapy and Prerequisites

inv-146: Conservative therapy expected before invasive ablation for OA

Document failure of conservative therapies as reflected in study populations; specific durations vary by indication and trial:

General expectation: Trials and guidelines generally expect prior conservative therapies (eg, analgesics, physical therapy, weight loss, assistive devices, intra‑articular injections when appropriate) to have been attempted and documented before considering ablative peripheral nerve procedures.

Policy and trials require documentation of failed conservative management; see indication‑specific trial criteria for details.

inv-147: Documentation of inadequate symptom relief from conservative measures is expected prior to RFA.

Documentation expectations prior to RFA or other ablative procedures:

Inadequate symptom relief documented: Medical record must document inadequate symptom relief from conservative measures (eg, failed medications, physical therapy, injections) and the rationale for proceeding to ablation.

Frequency, Repeat Procedures, and Procedural Limits

Genicular RFA / Cooled RFA — 6‑month Responder and Frequency Notes

Documented responder rate at 6 months (genicular C‑RFA)Approximately 70% responders at 6 months reported in multicenter U.S. cooled‑RFA trials

Frequency limits — trialsNo explicit numeric frequency limits for retreatment provided in trials or this excerpt

Imaging guidanceGenicular RFA procedures in trials were image‑guided (fluoroscopy/ultrasound); documentation expected

Procedure‑Specific Limits — Reference to Device Labeling and Codes Table

Procedure‑specific limits sourceProcedure‑specific frequency limits and constraints should be referenced from device labeling and the policy's Codes/Authorization tables

Device/regulatory guidance

Imaging and Procedural Guidance

Note

Not Covered / Investigational Procedures

NOT COVERED: Chemical neurolysis for multiple peripheral indications (including shoulder pain, intercostal neuralgia, inguinal neuralgia, plantar fasciitis, peripheral neuromas, orchialgia, and postherpetic neuralgia) lacks peer‑reviewed published literature in the reviewed evidence and is therefore considered not supported by adequate evidence in this policy.

NOT COVERED: Radiofrequency ablation, cryoneurolysis, and chemical neurolysis are listed as investigational for the enumerated indications in this policy (see policy investigational list); these modalities are therefore not established as medically necessary for those uses in the absence of stronger evidence.

NOT COVERED: Restatement — the policy lists multiple peripheral pain conditions for which ablative procedures are considered investigational; these listed uses should be treated as not covered absent contract language to the contrary.

NOT COVERED: Comparators such as platelet‑rich plasma or single intra‑articular injections are noted in trial contexts but are not established standard comparators for demonstrating durable superiority of ablation techniques; absence of high‑quality comparative data limits coverage for ablation when used in lieu of well‑established therapies.

NOT COVERED: Procedures without adequate randomized evidence or with only low‑quality case‑series data and inconsistent outcome measures may be determined not covered or investigational until higher quality evidence is available.

NOT COVERED: Interventions lacking adequate controlled evidence or without standardized outcome documentation (for example, some chemical neurolysis approaches reported only in case series) are not supported for routine coverage.

Policy Revision History

2017-01-01policy_effective

Original effective date of the policy 'Ablative Procedures of the Peripheral Nerves to Treat Pain' established.

2024-11review

Hayes annual evidence review of the iovera cryoneurolysis system completed (December 2024 referenced in document).

2025-11review_scheduledLatest

Policy review date noted (November 2025) per document header metadata.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyAblative Procedures of the Peripheral Nerves to Treat Pain

Policy CodePolicy 07.01.73

Change TypeNo material changes noted

Effective DateJan 1, 2017

Next Review DateN/A

Key ActionObtain prior authorization and document failed conservative therapies and baseline/posttreatment pain scores when requesting coverage.

SourceLink

On This Page

Cryoneurolysis evidence considerations: Systematic reviews and RCTs of iovera/cryoneurolysis show mixed quality evidence: some short‑term reductions in pain and opioid use, but inconsistent durability, unresolved technical parameters (nerves treated, freeze duration), and no consensus on repeat treatments.

Hayes reviews and RCTs summarized show limited durable benefit beyond early follow‑up.

Evidence varies by modality and indication.

6-12 months follow-up preferred

Per trial follow‑up recommendations and evidence‑quality considerations.

Chemical neurolysis for peripheral neuromas: No studies found; evidence insufficient.

No peer‑reviewed studies identified for chemical neurolysis in orchialgia or PHN; evidence insufficient and randomized trials are required.

No data available in the literature review.

diagnostic block confirmation suggested

Technique and long‑term safety data variable; documentation expected.

Document duration and response to prior therapies and reason for failure or intolerance.

Documentation Required

Authorization: Document Conservative Care and Diagnostic Block Response

When authorization is requested, include documentation of prior conservative care and diagnostic block response when used to select patients (e.g., ≥50% pain reduction with diagnostic genicular or spermatic cord block). Also supply baseline measures (BMI, VAS/NRS, WOMAC, KOOS, SF-12/36) and expected benefit.

Document diagnostic block response when used for selection (typically ≥50% reduction).
Provide baseline and anticipated post-procedure outcome measures (pain scores and functional scales).
Include BMI and duration/stability of analgesic regimens where applicable.

Prior Authorization

Prior Authorization Expectation

Prior authorization expectation: because evidence is limited or heterogeneous for many ablative and chemical neurolysis indications, prior approval reviews may request detailed trial documentation of conservative care, diagnostic block responses, baseline/outcome measures, and rationale for patient selection.

Preparedness to supply homogenous clinical population data and standardized pre/post measures.
Expectation that reviewers may request additional evidence when durability or comparative benefit is unclear.

Documentation Required

Prior Authorization: Patient Selection and Documentation

Patient selection and documentation: authorization requests should demonstrate appropriate selection (failed conservative therapy, documented baseline pain and function, diagnostic block response when applicable) and a homogeneous clinical population for the indication.

Required elements: indication, targeted nerve(s), prior treatments tried and failed, baseline pain (VAS/NRS) and functional scores.
When used preoperatively (eg, cryoneurolysis prior to TKA), include operative plan and anticipated benefit.

Documentation Required

Prior Conservative Therapy and Baseline Pain Required

For peripheral ablative procedures, prior conservative therapy and baseline pain/function documentation are required. Provide quantifiable pre- and post-treatment measures and duration of prior conservative trials to support medical necessity.

Include validated scales: VAS/NRS, WOMAC, Oxford Knee Score, KOOS, LKS, AOFAS, SF-12/36 as applicable.
Specify duration of conservative therapy and details of interventions (PT, medications, injections).

Documentation Required

Outcome and Prior Treatment Documentation

Outcome and prior treatment documentation should include baseline pain scores, standardized functional measures, documentation of prior therapies and their durations, and follow-up outcome assessments to demonstrate clinical benefit and durability.

Pre- and post-treatment VAS/NRS at defined timepoints (immediate, 1 month, 6 months, 12 months when available).
Functional outcome measures (WOMAC, KOOS, Oxford Knee Score, AOFAS, SF‑12/36) and opioid consumption where relevant.
For perioperative uses, include perioperative opioid use, length of stay, and discharge criteria.

Prior Authorization

Prior Authorization — Require Conservative Therapy Failure and Indication Justification

Prior authorization for investigational indications will typically require demonstration of conservative therapy failure and justification of indication; investigational procedures may be denied if not a covered benefit or evidence is insufficient.

If indication is listed as investigational in policy, prior approval alone may not confer coverage — verify member benefits.
Provide clear justification for use when conservative therapies have failed and alternative options are limited.

Prior Authorization

Preauthorization: Supply Indication and Expected Benefit

Preauthorization supply: when requesting preauthorization, supply the clinical indication, targeted procedure, anticipated benefit, and supporting documentation (prior therapies, diagnostic block response, baseline/outcome measures).

Include expected timeframe for benefit and any planned perioperative analgesia strategy.
Attach relevant operative/procedure plan when used in perioperative settings (eg, Nuss, TKA).

Denial Risk

Benefit / Exclusion Risk

Benefit/exclusion risk: benefit determinations depend on the member's contract. Services not covered by the contract or listed as investigational may be denied even if prior authorization is requested.

Verify member benefits at time of service; exclusions, limitations, or exceptions may apply.
Investigational categorizations in this policy indicate that payment is unlikely under standard benefits.

Documentation Required

Conservative Treatment and Selection Criteria

Conservative treatment and selection criteria: conservative therapies are expected before ablation. Documentation should show trials of standard therapies (medications, PT, injections) and reasons for proceeding to ablative treatment.

Document specific conservative treatments attempted, duration, and response.
When step therapy is relevant, attempt standard therapies first and document rationale for escalation.

Denial Risk

Evidence Limitations May Trigger Denial

Evidence limitations may trigger denial: heterogeneity of studies, short follow-up, small sample sizes, and lack of blinding or credible methodology increase the risk that requests will be denied.

Be prepared to supply longer-term outcome data and robust standardized measures when available.
Trials with small samples, short follow-up, or missing comparator data are less persuasive for coverage.

Denial Risk

Evidence Uncertainty May Lead to Denial

Evidence uncertainty may lead to denial: when the net clinical benefit is unclear, reviewers may determine the service is not medically necessary or is investigational and not covered.

This is especially relevant for chemical neurolysis indications where evidence is lacking for many conditions.

Denial Risk

Evidence / Documentation Insufficiency

Evidence and documentation insufficiency: missing quantifiable pre/post measures, absent diagnostic block response, or incomplete prior conservative therapy records may lead to denial of authorization or claim adjudication.

Ensure inclusion of baseline and follow-up pain/function scores, diagnostic block results, and a clear history of prior therapies.

Denial Risk

Denial Risk From Missing Pre-procedure Criteria

Denial risk from missing pre-procedure criteria: lack of documented diagnostic block response (when used) or failure to document conservative therapy attempts and baseline measures can result in denial.

If diagnostic blocks are part of selection criteria, document ≥50% pain relief and timing relative to the procedure.
Document why conservative options were inadequate or inappropriate.

Denial Risk

Chemical Neurolysis Evidentiary Risk

Chemical neurolysis evidentiary risk: for many indications (hip, intercostal, orchialgia, plantar fasciitis, peripheral neuromas, PHN, shoulder) published evidence for chemical neurolysis is lacking; requests for chemical neurolysis are likely to face denial absent strong supporting data.

No randomized trials identified for chemical neurolysis for multiple peripheral indications; include high-quality supportive evidence if available.

Denial Risk

Evidence Quality Concern

Evidence quality concern: heterogeneity, low methodological quality, and limited sample sizes in the literature raise concern about reliability of effect estimates and may lead to noncoverage decisions.

Provide higher-quality, longer-duration data and standardized outcome reporting to mitigate evidence-quality concerns.

Note

No Denial Criteria in References

No denial criteria are provided in the References section of this policy; consult the policy body and payer-specific benefit language for coverage determinations.

References list does not specify authorization or denial rules; use policy content and contract language for determinations.

Prior Authorization

Prior Approval and Coding Reference

Prior approval and coding reference: obtain prior approval per payer tables and include relevant procedure and diagnosis codes in the submission.

Attach pertinent CPT/HCPCS/ICD-10 codes and clinical documentation to the prior authorization request.
Refer to the Codes table for code-level guidance.

Documentation Required

Document Baseline and Follow-up Quantifiable Outcomes

Document baseline and follow-up quantifiable outcomes: include pre- and post-treatment pain scores and validated functional measures at specified follow-up intervals to support claims of efficacy and durability.

Typical follow-up intervals: immediate (procedural success), 1 month, 3–6 months, and 12 months to evaluate durability.
Include opioid consumption and other objective perioperative measures when applicable.

Documentation Required

Required Clinical Documentation

Required clinical documentation: authorization and retrospective review should include indication, targeted nerve(s), procedure details, prior conservative treatments, diagnostic block(s) and response, baseline pain/function measures, BMI where relevant, and expected benefit.

Procedure details: device type, nerves targeted, number of cycles/lesions, imaging/guidance used.
Include dates and providers for prior treatments and diagnostic blocks.

Documentation Required

Required Clinical Outcome Documentation

Required clinical outcome documentation: include standardized pre/post measures and duration of prior conservative therapy; for perioperative uses include perioperative opioid use, LOS, and complications.

Pre/post standardized measures (VAS/NRS, WOMAC, KOOS, Oxford Knee Score, AOFAS, SF‑12/36) with dates.
Perioperative items: total opioid MME, LOS, discharge criteria, and adverse events.

Documentation Required

Required Outcome Documentation

Required outcome documentation: provide baseline and post-treatment validated measures and follow-up to demonstrate benefit and durability; incomplete outcomes data weakens the authorization case.

Report changes with means, standard deviations, and relevant p-values when available.
For observational registry or retrospective studies submitted as support, provide demographics, follow-up duration, and complication rates.

Documentation Required

Pain Scores and Follow-up Documentation

Pain scores and follow-up documentation: include immediate and longer-term pain scores (VAS/NRS) and functional assessments at predefined intervals to support clinical effectiveness claims.

Immediate procedural success and longer-term assessments at 1, 3, 6, and 12 months where available.
Document any repeat procedures and their timing.

Documentation Required

Pain Measurement and Follow-up Documentation

Pain measurement and follow-up documentation for durability: supply baseline and follow-up assessments to support durability of response; short follow-up may be insufficient for coverage of denervation therapies.

Durability expectations: initial procedural success within days and at least 6–12 months follow-up to assess longer-term benefit.

Documentation Required

Suggested Documentation for Perioperative Pain Management

Suggested documentation for perioperative pain management: when used pre/intra/postoperatively (eg, cryoablation for TKA or Nuss), include operative report, analgesia plan, perioperative opioid consumption, length of stay, and discharge criteria.

Provide inpatient and outpatient opioid MME, LOS, complications, and functional recovery measures.
Include protocolized perioperative analgesia elements (nerve blocks, multimodal meds) to contextualize outcomes.

Documentation Required

Consideration of Nonsurgical Modalities

Consideration of nonsurgical modalities: document trials of nonsurgical options (exercise, weight loss, PT, medications, injections) and rationale for escalation to ablative therapies.

Describe duration and response to each nonsurgical modality.
If step therapy applies, document attempts and reasons for not completing or failing those steps.

Documentation Required

Conservative Therapy Expected Prior to Ablative Procedures

Conservative therapy expected prior to ablative procedures: trials of medications, physical therapy, and injections are expected; document failure or intolerance before proceeding to ablation.

Record specific therapies tried, dates, providers, and objective response.
When applicable, document contraindications to further conservative care.

Step Therapy

Step Therapy — Attempt Standard Therapies First

Step therapy — attempt standard therapies first: when applicable, step therapy should be followed with documentation of each step and rationale for escalation to ablative interventions.

Document dates and outcomes of each step-therapy element (eg, NSAIDs → PT → injections).

Documentation Required

Conservative Therapy Prerequisites

Conservative therapy prerequisites: authorization reviewers expect documentation of relevant conservative measures (NSAIDs, antidepressants for neuropathic pain, PT, injections) and their duration prior to approving ablative procedures.

For neuropathic conditions (eg, PHN, orchialgia), document trials of guideline‑recommended pharmacotherapies (eg, TCAs, gabapentinoids) and outcomes.

Documentation Required

Comparative Context

Comparative context: many studies compared ablation or cryoablation to standard analgesic pathways (eg, thoracic epidural for Nuss procedure); when submitting evidence, provide comparative data and context versus standard of care.

When available, include comparative outcomes such as LOS, opioid consumption, pain scores, and complication rates versus standard approaches.

Documentation Required

Conservative Therapy Expected Before Ablation

Conservative therapy expected before ablation: in general, guideline and policy context favor a conservative‑first approach; document failure of conservative management and rationale for ablation.

Ensure clear timeline from conservative therapies to diagnostic blocks to ablative intervention in the record.

Cryoneurolysis / CryoablationApplication of extreme cold (approximately −20°C to −100°C) to peripheral sensory nerves causing Wallerian degeneration with subsequent regeneration (recovery typically ~3–5 months)

Iovera device contextPercutaneous handheld cryoablation systems (eg, iovera) deliver targeted cold to superficial peripheral nerves for temporary analgesia

Clinical usesUsed presurgically (eg, prior to TKA) and for chronic peripheral neuropathic pain in studied trials

Chemical Neurolysis — Definition (phenol, alcohol, glycerol)

Chemical neurolysis — agentsInjection of neurolytic agents such as phenol, alcohol, or glycerol to destroy nerve fibers and provide local anesthetic/neurolytic effect

MechanismChemical-induced nerve destruction of small nerve fibers producing prolonged analgesia; technique and concentrations vary by report

Clinical contextConsidered for peripheral pain syndromes but peer‑reviewed evidence is limited or lacking for many indications

Radiofrequency Ablation — Additional Technical Points

RFA — technical descriptionNeedle electrode inserted percutaneously; high‑frequency current generates a thermal sphere of coagulation necrosis to denervate sensory fibers

Temperature / duration (standard RFA)Typical tissue temperatures reported 70–90°C with electrode application durations described ~90–130 seconds

Distinction from PRFPRF is considered non‑ablative/neuromodulatory compared with continuous thermal RFA

Cooled RFA / Pulsed RFA — Definitions and Rationale

Cooled RFA (C‑RFA)Water circulates through the RF electrode to cool the tip; probe temperature ~60°C while creating larger lesion volumes than standard RFA

Pulsed RFA (PRF)Delivers short pulses (eg, 20 ms every 30 sec) with tissue temperatures around 42°C; intended to limit tissue destruction

Clinical rationaleCooled probes aim to increase area of denervation to accommodate variable genicular nerve anatomy

Cryoneurolysis — Technical Temperatures and Recovery

Cryoneurolysis — temperature and recoveryFreeze temperatures approximately −20°C to −100°C induce Wallerian degeneration; peripheral nerve structure preserved allowing regeneration over ~3–5 months

Procedural devicesPortable handheld cryoablation systems and operative cryoICE/cryoSPHERE probes are used for percutaneous or intraoperative applications

Clinical implicationEffect is expected to be temporary with potential need for repeat treatment; repeat benefit not well established

Chemical Neurolysis — Agents and Mechanism

Chemical neurolysis — agents listedCommon agents: phenol, alcohol, glycerol used to produce neurolytic destruction and analgesia

Mechanism summaryCauses nerve fiber destruction with local anesthetic effect on small fibers; technique details vary across reports

Evidence notePeer‑reviewed evidence is sparse for many peripheral applications; considered investigational for several indications

Cooled‑RFA (C‑RFA) — Description

Cooled‑RFA (C‑RFA) descriptionA variant of RFA that uses a cooled probe to create a larger lesion area, proposed to improve efficacy for variably located genicular nerves

Clinical useEvaluated in multicenter trials for genicular nerve ablation in knee OA with reported higher responder rates at 6 months versus controls

Device/regulatory contextCOOLIEF Cooled RF system (K163461) cleared by FDA for genicular nerve lesions with prior diagnostic block >50% relief

Genicular Nerves (GN) — Definition

Genicular nerves — definitionSensory branches supplying the knee commonly targeted: superomedial, inferomedial, and superolateral genicular nerves

Target rationaleThese branches carry articular sensory fibers and are targeted to reduce knee OA pain via denervation

Anatomic variabilityLocations are variable across patients, motivating use of imaging guidance and larger lesion techniques (eg, C‑RFA)

Responder — Definition (>50% NRS reduction)

Responder definition used in trials>50% reduction in pain on NRS/VAS is commonly defined as a study 'responder' endpoint

UsageResponder thresholds applied in RCTs and observational studies to define clinically meaningful pain improvement at intervals such as 3 and 6 months

Documentation implicationTrials and prior‑authorization expectations reference >50% pain reduction on diagnostic block or as outcome responder definition

Cryoneurolysis (iovera) — Description and Context

Iovera (cryo) device descriptionIovera is a percutaneous handheld cryoablation system that applies targeted cold to superficial peripheral nerves for temporary analgesia (used in some knee OA/TKA studies)

Evidence contextRCTs and systematic reviews of iovera report short‑term pain/function improvements up to ~90 days; durability and repeat treatment benefit not established

Regulatory noteFDA cleared additional labeling in 2021 for cryo nerve block therapy in adolescents 12–21 years for intercostal nerve applications

Cooled RFA — Additional Description

Cooled RFA — additional contextCooled RF referenced in multiple clinical studies and dossiers as an approach to generate larger lesions for genicular and articular sensory branch ablation

Mechanistic noteWater‑cooled probe maintains lower tip temperature while allowing greater energy delivery to enlarge lesion size

Clinical trial evidenceMulticenter trials using cooled‑RFA reported ~70% responders at 6 months in U.S. studies

AFCN / ISN / Genicular Nerves — Abbreviations and Targets

AFCN / ISN / GN abbreviationsAFCN = anterior femoral cutaneous nerve; ISN = infrapatellar branch of the saphenous nerve; GN = genicular nerves (superomedial, inferomedial, superolateral)

Clinical targetingAFCN and ISN commonly targeted in preoperative cryoneurolysis for TKA; genicular nerves targeted for OA knee RFA

DocumentationProcedure reports should identify targeted nerves (AFCN, ISN, GN) and guidance modality used

Chemical Neurolysis — Detailed Definition

Chemical neurolysis — detailed definitionInjection of phenol, alcohol, or glycerol to chemically destroy peripheral nerve fibers producing neurolytic analgesia; technique details (agent concentration, volume, target) vary across reports

Clinical evidencePeer‑reviewed evidence is limited or absent for many peripheral indications; considered investigational for multiple uses

Intended effectProduces lasting nerve destruction compared with temporary modalities, but safety and long‑term effects depend on target and agent

Cryoneurolysis — Alternate References and Context

Cryoneurolysis — alternate referencesMultiple case series and technical reports (Ilfeld et al, Wolter et al) describe percutaneous cryoneurolysis approaches; evidence includes RCTs for some perioperative uses

Perioperative evidenceData for intercostal cryoablation in Nuss procedure include RCTs and meta‑analyses showing reduced LOS and opioid use with heterogeneity

Technique variabilityApproaches vary (ultrasound‑guided percutaneous vs intraoperative thoracoscopic) and are procedure‑dependent

Radiofrequency Ablation (RFA) — Restated

RFA restated — mechanismHigh‑frequency electrical current applied via percutaneous electrode generates thermal coagulation necrosis to denervate sensory nerves and reduce pain

Procedure parametersReported electrode application times ~90–130 seconds with target tissue temperatures depending on modality (standard ~70–90°C)

Clinical applicationApplied to genicular and other peripheral sensory branches for OA and neuropathic pain in trials

Ablative Procedures — Definition Grouping

Ablative procedures — groupingIncludes radiofrequency ablation (standard, cooled, pulsed), cryoneurolysis/cryoablation, and chemical neurolysis (phenol, alcohol, glycerol)

PurposeInterventions aim to interrupt or destroy peripheral sensory nerve function to reduce chronic pain symptoms

Outcome measuresEfficacy assessed by patient‑reported pain scales (VAS/NRS) and functional scores (WOMAC, HOOS, SF‑12/36)

Clinical Outcome Measures — VAS/NRS, WOMAC, HOOS, SF-12/36

Clinical outcome measuresPrimary measures: VAS or NRS for pain; functional instruments include WOMAC, HOOS, Oxford Knee Score; health‑related QOL: SF‑12/36

Follow‑up timingImmediate/early (days–weeks) for procedural success and at least 6 months to 1 year (preferably ≥12 months) to assess durability

Responder metricClinically meaningful responder often defined as >50% pain reduction on NRS/VAS

Cryoneurolysis — Alternate Definition

Cryoneurolysis — alternate definitionPercutaneous or intraoperative freezing of sensory nerves to produce reversible denervation for months; devices and approaches vary by indication

Clinical use notesUsed for perioperative analgesia (eg, Nuss) and some chronic peripheral pain syndromes; evidence quality varies by use

Recovery expectationNerve regeneration typically occurs over months (3–5 months) after Wallerian degeneration

Chemical Neurolysis — Alternate Definition

Chemical neurolysis — alternate definitionNeurolytic injections (phenol, alcohol, glycerol) producing chemical destruction of nerve fibers with local anesthetic effect; used variably across peripheral pain syndromes

Evidence gapsMany indications lack randomized data; technique details and outcomes vary across case series and reports

Safety considerationsPotential for lasting nerve injury and off‑target effects depending on agent and proximity to motor fibers

RFA / Cryoneurolysis / Chemical Neurolysis — Group Summary

RFA / cryoneurolysis / chemical neurolysis — summaryInterventional modalities form a class of ablative or neuromodulatory procedures targeting peripheral sensory nerves; techniques differ by mechanism (thermal, cold, chemical)

Selection and evidenceTrials and observational studies vary widely by indication, technique, and follow‑up; many indications remain investigational

Documentation expectationBaseline and postprocedure standardized pain/function measures and prior conservative therapy documentation are recommended

Inguinal/Orchialgia Population Definitions

Inguinal neuralgia population definitionChronic orchialgia population described separately; inguinal neuralgia refers to ilioinguinal/iliohypogastric neuropathic pain after surgery or trauma

Orchialgia population noteChronic orchialgia defined as chronic testicular/scrotal pain including post‑vasectomy syndromes considered in RCTs

Trial selectionTrials required baseline pain thresholds and prior conservative therapy failure for enrollment

Plantar Fasciitis — Population Details

Plantar fasciitis population definitionAdults with chronic plantar heel pain, focal tenderness at medial calcaneal tubercle, worst on first steps; targeted in RFA RCTs

Trial evidenceTwo double‑blind sham‑controlled RCTs evaluated RFA for plantar fasciitis with short‑term benefits reported

Outcome measuresVAS and AOFAS/functional scores commonly used

Interventions — Restated Listing

Interventions listing (restated)RFA (standard, cooled, pulsed), cryoneurolysis/cryoablation, and chemical neurolysis (phenol, alcohol, glycerol) were the primary interventions reviewed

Application sitesGenicular nerves, AFCN/ISN, ilioinguinal/iliohypogastric nerves, intercostal nerves, peripheral neuromas, dorsal root ganglia in select reports

Evidence levelRCTs available for some indications; many rely on observational data or case series

Populations of Interest

Populations of interestKnee OA, hip OA, chronic shoulder pain, intercostal and inguinal neuralgias, plantar fasciitis, peripheral neuromas, chronic orchialgia, postherpetic neuralgia

Selection criteria commonalitiesMost trials required failed conservative therapy and quantifiable baseline pain/function measures

Evidence statusRCTs exist for several indications but many areas rely on case series or observational data

Interventions — Restated

Interventions restatedAblative interventions considered: thermal RFA (standard/cooled), pulsed RFA, cryoneurolysis/cryoablation, chemical neurolysis (phenol/alcohol/glycerol)

Intended outcomeReduce sensory nerve transmission to relieve chronic peripheral pain and improve function

Evidence variabilityStrength of evidence varies by indication and modality; many indications remain investigational

Relevant Outcomes — Primary and Timing

Relevant outcomes — primaryPain severity (VAS/NRS) and functional limitation scores (WOMAC, HOOS, Oxford) are primary outcomes; follow‑up timing includes days for immediate effect and at least 6 months for durability

Responder thresholdResponder often defined as >50% reduction in pain on NRS/VAS

Secondary outcomesOpioid consumption, length of stay (perioperative cryo), and adverse events reported in trials and observational studies

Pulsed RFA — PRF Description and Trial Context

Pulsed RFA (PRF) — description and trialsPRF delivers short, non‑continuous RF pulses producing neuromodulatory effects; small RCTs in PHN and inguinal neuralgia report short‑term pain improvements

Effect durationReported effects begin within days and may persist 2–6 months in small trials (PHN) or longer in some inguinal neuralgia reports

SafetyNo major safety signals reported in small PRF RCTs, but sample sizes and follow‑up are limited

Cryoneurolysis / Cryoablation — Restated Context

Cryoneurolysis / cryoablation — restatedFreezing peripheral nerves (−20° to −100°C) producing Wallerian degeneration and temporary analgesia; used perioperatively (Nuss, TKA) and for chronic pain

Device examplesCryoICE, cryoSPHERE, iovera and related probes described in literature and trials

Evidence noteRCTs and meta‑analyses exist for perioperative intercostal cryoablation (Nuss) showing benefits but with heterogeneity; repeat treatment benefit unclear

Intercostal Nerve Cryoablation (INC) — Definition and Evidence

Intercostal nerve cryoablation (INC)Focused intraoperative cryoablation of intercostal nerves to reduce postoperative pain (eg, during Nuss procedure); studies report reduced LOS and opioid use

Evidence summaryMeta‑analyses and RCTs show shorter hospital stay and lower opioid requirements vs thoracic epidural but with high heterogeneity and variable complication rates

Procedural settingUsually intraoperative thoracoscopic or open approaches; imaging guidance not universally specified

Radiofrequency Ablation (RFA) — Restated Summary

RFA restated — summaryPercutaneous thermal application to targeted sensory nerves to produce coagulative necrosis and analgesia; variants include cooled and pulsed approaches

Indications studiedGenicular nerves for knee OA, dorsal root ganglia and peripheral nerves for neuropathic pain syndromes

Follow‑up needsDurability beyond 6–12 months uncertain; trials recommend at least 12 months follow‑up for durability assessment

Cooled Radiofrequency Ablation — References

Cooled RFA referencesCooled RFA is referenced in multiple clinical studies, dossiers and reviews as an approach to increase lesion size and potentially efficacy for genicular nerve ablation

Clinical trial evidenceMulticenter manufacturer‑sponsored and independent trials evaluated cooled RFA versus injections/sham with reported short‑term benefits

Technical rationaleLarger lesion may improve coverage of variable nerve anatomy

Cryoanalgesia / Cryoneurolysis — References

Cryoanalgesia / cryoneurolysis referencesNumerous case series, technical reports and some RCTs describe cryoneurolysis for perioperative and chronic applications (Ilfeld, Wolter, others)

Device examplesCryoICE, cryoSPHERE and iovera systems reported in literature and regulatory filings

Clinical contextsUsed preoperative (TKA), intraoperative (Nuss) and for chronic peripheral neuropathic pain

Failure of Conservative Therapies — Documentation Expectation

Document conservative therapy failure per studiesTrials generally enrolled patients who had failed conservative management (eg, physical therapy, analgesics, intra‑articular injections); specific durations varied by trial

Conservative measuresIncluded analgesics (≤60 mg morphine equivalence stable for 2 months in some trials), PT, and intra‑articular steroid/viscosupplementation

ImplicationDocumentation of failed conservative therapy is expected when aligning with trial‑based candidacy

Documentation supports alignment with trial eligibility and payer review expectations.

inv-148: Documented trial of conservative therapy required per trial criteria (stable for 2 months for oral analgesics)

Trial-specified conservative therapy requirements that informed enrollment criteria:

Documented trial per trial criteria: Trials frequently required prior conservative measures including physical therapy, oral analgesics (stable for 2 months, often ≤60 mg morphine equivalent), and intra‑articular steroid or viscosupplementation prior to enrollment.stable for 2 months for oral analgesics

Reflects common RCT eligibility provisions.

inv-149: Must document prior conservative treatment attempts and rationale for proceeding to ablation

Clinical requirement summarized from study comparators and evidence selection:

Prior conservative treatment and rationale: Providers must document prior conservative treatment attempts and the clinical rationale for proceeding to ablative procedures in the medical record.

Consistent with trial comparators and guideline recommendations.

inv-150: Placeholder conservative criteria

Operational expectation for documentation before ablative procedures:

Documentation of prior conservative therapy attempts: Medical record should include prior conservative management attempts and documentation of refractory pain (eg, failed medications, physical therapy, nerve blocks) consistent with study inclusion and comparator arms.

Supports prior authorization and medical necessity review.

inv-151: Conservative therapies should be attempted and documented prior to ablative procedures

Expectation summarized from trial designs and guideline context:

Conservative therapies attempted and documented: Conservative therapies (analgesics, physical therapy, weight loss, intra‑articular corticosteroid or viscosupplementation where applicable) should be attempted and documented prior to considering ablative procedures.

Reflects standard-of-care comparators and trial prerequisites.

inv-152: Documented failure of conservative therapy is expected before ablative procedures, per study comparators and eligibility.

Expectation based on study comparators and inclusion criteria:

Documented failure expected before ablation: Documented failure of appropriate conservative therapy is expected before proceeding to ablative procedures; documentation should reflect prior noninvasive and injection‑based therapies as relevant to the condition.

Trial comparators and professional guidelines support this requirement.

inv-155: Document failed conservative therapy prior to ablative procedures (>= 3-6 months)

Timing expectations derived from case series inclusion and trial context:

Minimum conservative treatment duration: Case series and some trial enrollment criteria commonly required prior failure of multiple conservative treatments and symptom duration; available reports reference minimum durations of ~3–6 months for failed conservative therapy prior to ablation consideration.>= 3-6 months

Duration expectations vary by indication and study.

inv-156: Documented failure or inadequate response to appropriate conservative therapies is expected prior to considering ablative procedures.

General expectation from evidence selection for prior management:

Document failure or inadequate response to appropriate conservative therapies: Documented failure or inadequate response to appropriate conservative therapies (eg, NSAIDs, physical therapy, injections, and diagnostic/therapeutic nerve blocks) is expected prior to considering ablative procedures.

Consistent with study enrollment criteria across indications.

FDA 510(k) for COOLIEF (K163461) includes indications and diagnostic block criteria that inform procedural selection

Coding referenceSee Codes table in the policy for applicable CPT/HCPCS identifiers and any payer authorization rules

Imaging in Trials and Frequency Limits — Notes

Trial imaging and frequency reportingRFA procedures in randomized trials were performed with image guidance (fluoroscopy or ultrasound); trials did not specify numeric frequency limits for retreatment

Documentation expectationImaging guidance used in trials should be documented in procedure reports for safety and reproducibility

No frequency dataClinical studies and references in this excerpt do not define formal limits on number/timing of repeat RFA or cryoneurolysis treatments

Repeat Treatments — Cryoneurolysis (iovera) and Genicular RFA

Repeat treatments — evidence statusClinical benefit and optimal timing for repeat iovera cryoneurolysis and genicular RFA are not established; repeat procedures are considered investigational until evidence supports retreatment

Perioperative cryoFor intercostal cryo in Nuss procedures, several studies show reduced LOS and opioid use but repeat procedural relevance differs (usually single intraoperative application)

Documentation implicationRequests for repeat ablative procedures should include supporting outcome data and rationale due to limited retreatment evidence

Cryoanalgesia / Cryoneurolysis — Frequency Notes

Cryoanalgesia repeat frequencyNo specified numeric frequency limits for cryoneurolysis in this excerpt; repeat treatment benefit not established

Device considerationsDevice labeling and trials focus on single‑application perioperative use or single courses for chronic pain studies

Clinical cautionClinical teams should document measured benefit prior to considering retreatment

Imaging Guidance — Expectation for RFA Procedures

Imaging and documentation expectationRFA procedures in cited studies were performed under fluoroscopy and/or ultrasound guidance; documentation of imaging guidance is expected for procedural claims

Target localizationBecause genicular nerve anatomy is variable, imaging and technique (eg, cooled probes) are used to optimize lesion placement

Safety implicationImaging guidance helps avoid adjacent neurovascular structures and should be recorded in operative/procedure notes

Pulsed RFA — Retreatment Patterns in Trials

Pulsed RFA retreatment in trialsSome PRF trials (eg, Makharita inguinal neuralgia) permitted repeated PRF per protocol (patients could receive up to 3 blocks in control group); no formal numeric frequency limit established in policy excerpt

Clinical implicationRetreatment patterns in trials may inform practice but do not mandate payer frequency limits

DocumentationIf repeat PRF performed, document trial protocol alignment and clinical response

NOT COVERED: Chemical neurolysis for inguinal neuralgia is explicitly unsupported due to lack of peer‑reviewed studies and would be considered investigational.